FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
AffiliationDepartment of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto
MetadataShow full item record
AbstractFOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.
CitationFOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. 2016, 115 (6):649-54 Br J Cancer
JournalBritish Journal of Cancer